Merck & Co., Inc. (MRK) Quick Ratio (Acid-Test): 1.30
Is Merck & Co., Inc.’s quick ratio (acid-test) high or low?
Merck & Co., Inc.'s quick ratio (acid-test) of 1.30 is 20% above its 5-year average of 1.09, near the high end of its 5-year range (0.81–1.30).
The quick ratio (acid-test) for Merck & Co., Inc. (MRK) is 1.30 as of Wednesday, June 10, 2026. It is above its 12-month average by 6.12% (1.23).
MRK Quick Ratio (Acid-Test) Chart
MRK Average Quick Ratio (Acid-Test) Chart
MRK Current vs Average Quick Ratio (Acid-Test) Chart
MRK Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
1.30
QUICK RATIO (ACID-TEST) AVG TTM
1.23
QUICK RATIO (ACID-TEST) AVG 3Y
1.17
QUICK RATIO (ACID-TEST) AVG 5Y
1.09
QUICK RATIO (ACID-TEST) AVG 10Y
1.11
QUICK RATIO (ACID-TEST) AVG 15Y
1.25
QUICK RATIO (ACID-TEST) AVG 20Y
1.24
CURRENT VS TTM AVG
+6.12%
CURRENT VS 3Y AVG
+11.11%
CURRENT VS 5Y AVG
+19.82%
CURRENT VS 10Y AVG
+16.64%
CURRENT VS 15Y AVG
+3.69%
CURRENT VS 20Y AVG
+4.44%
MRK Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | — | 1.30 | 1.23 | 1.17 | 1.09 |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 0.79 | 0.81 | 0.80 | 0.79 |
| AbbVie Inc. (ABBV) | $399.54B | 0.56 | 0.56 | 0.68 | 0.69 |
| Amgen Inc. (AMGN) | $185.96B | 0.90 | 0.93 | 1.02 | 1.14 |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 1.53 | 1.41 | 1.34 | 1.37 |
| Abbott Laboratories (ABT) | $158.94B | 1.18 | 1.21 | 1.20 | 1.26 |
| Gilead Sciences, Inc. (GILD) | $155.82B | 1.31 | 1.38 | 1.29 | 1.26 |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 3.96 | 3.59 | 3.74 | 4.30 |
| Pfizer Inc. (PFE) | $146.36B | 0.87 | 0.90 | 0.87 | 0.95 |
| Danaher Corporation (DHR) | $133.37B | 1.51 | 1.28 | 1.37 | 1.36 |
Liquidity Comparison
Quick Ratio
1.30
Excludes inventory
Current Ratio
1.54
Includes inventory
Merck & Co., Inc. Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Merck & Co., Inc. (MRK)?
- The quick ratio (acid-test) for MRK stock is 1.30.
- Is Merck & Co., Inc.'s quick ratio (acid-test) high or low?
- Merck & Co., Inc.'s quick ratio (acid-test) of 1.30 is 20% above its 5-year average of 1.09, near the high end of its 5-year range (0.81–1.30).
- What is the TTM average quick ratio (acid-test) for Merck & Co., Inc. (MRK)?
- The TTM average quick ratio (acid-test) for MRK stock is 1.23.
- What is the 3Y average quick ratio (acid-test) for Merck & Co., Inc. (MRK)?
- The 3Y average quick ratio (acid-test) for MRK stock is 1.17.
- What is the 5Y average quick ratio (acid-test) for Merck & Co., Inc. (MRK)?
- The 5Y average quick ratio (acid-test) for MRK stock is 1.09.
- What is the 10Y average quick ratio (acid-test) for Merck & Co., Inc. (MRK)?
- The 10Y average quick ratio (acid-test) for MRK stock is 1.11.
- What is the 15Y average quick ratio (acid-test) for Merck & Co., Inc. (MRK)?
- The 15Y average quick ratio (acid-test) for MRK stock is 1.25.
- What is the 20Y average quick ratio (acid-test) for Merck & Co., Inc. (MRK)?
- The 20Y average quick ratio (acid-test) for MRK stock is 1.24.
Merck & Co., Inc. Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 1.30 |
| 2024-12-31 | 1.15 |
| 2023-12-31 | 1.00 |
| 2022-12-31 | 1.23 |
| 2021-12-31 | 1.02 |
| 2020-12-31 | 0.81 |
| 2019-12-31 | 0.97 |
| 2018-12-31 | 0.92 |
| 2017-12-31 | 1.06 |
| 2016-12-31 | 1.50 |
| 2015-12-31 | 1.30 |
| 2014-12-31 | 1.47 |
| 2013-12-31 | 1.65 |
| 2012-12-31 | 1.54 |
| 2011-12-31 | 1.66 |
| 2010-12-31 | 1.48 |
| 2009-12-31 | 1.30 |
| 2008-12-31 | 1.19 |
| 2007-12-31 | 1.07 |
| 2006-12-31 | 1.06 |
| 2005-12-31 | 1.46 |
| 2004-12-31 | 0.99 |
| 2003-12-31 | 0.94 |
| 2002-12-31 | 0.92 |
| 2001-12-31 | 0.81 |
| 2000-12-31 | 1.06 |
| 1999-12-31 | 0.96 |
| 1998-12-31 | 1.25 |
| 1997-12-31 | 1.09 |
| 1996-12-31 | 1.16 |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis